In its 13F for Q4 2024 (holdings as of December 31, 2024, filed February 14, 2025), Rosalind Advisors, Inc. reported 28 stock positions worth $185.7 million . Its top holding was Delcath Systems (DCTH) at 17.2% of the portfolio, followed by Myomo (MYO, 10.4% ) and Mediwound (MDWD, 6.0% ). Compared with Q3 2024, it opened 11 new positions, sold out of 12, added to 6 and reduced 7. The biggest buy was a new position in Chimerix (CMRX) and the biggest sale an exit from Cormedix (CRMD).
Location TORONTO, A6
CIK 0001622627
Portfolio Value $185.7M (Q4 2024) Holdings 28 stocks · $185.7M Holdings quarter Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024
Stock % Of Portfolio ▼ Shares Held Total Value Change vs Q3 2024 DCTH Delcath Systems Inc. 2,650,389 $31.9M No change MYO Myomo Inc. 2,998,945 $19.3M Reduce -0.7% MDWD Mediwound Ltd. 628,050 $11.2M No change CMRX Chimerix Inc. 3,050,000 $10.6M New XERS Xeris Biopharma Holdings Inc. 3,104,995 $10.5M No change ABEO Abeona Therapeutics Inc. 1,805,390 $10.1M Reduce -1.4% OCUL Ocular Therapeutix Inc. 1,128,700 $9.6M Add +27.5% URGN Urogen Pharma Ltd. 870,000 $9.3M New SVRA Savara Inc. 2,654,944 $8.2M New FENC Fennec Pharmaceuticals Inc. 1,259,876 $8.0M New HELP Cybin Inc. 810,918 $7.2M New VRNA Verona Pharma Ltd. 150,000 $7.0M Reduce -45.5% NSPR Inspiremd Inc. 2,495,783 $6.6M Reduce -0.7% OPTINOSE INC 876,996 $5.9M Add +58.7% PROF Profound Medical Corp. 692,185 $5.2M Add +42.4% VSTM Verastem Inc. 900,000 $4.7M New TRVI Trevi Therapeutics Inc. 1,062,500 $4.4M Add +41.7% REPL Replimune Group Inc. 260,000 $3.1M New PYPD Polypid Ltd. 1,018,021 $3.1M Add +49.9% CMPS Compass Pathways PLC 707,625 $2.7M Reduce -9.4% KALV Kalvista Pharmaceuticals Inc. 303,864 $2.6M No change ACOG Alpha Cognition Inc. 252,753 $1.5M New FLNA Filana Therapeutics Inc. filed as CASSAVA SCIENCES INC 417,400 $985K New BFRI Biofrontera Inc. 811,918 $885K Add +63.9% KPRX Kiora Pharmaceuticals Inc. 250,555 $827K New TLPH Talphera Inc. 613,939 $322K Reduce -19.1% OWLT Owlet Inc. 49,441 $220K Reduce -81.7% RLMD Relmada Therapeutics Inc. 100,000 $52K New
Options reported separately and not counted above: CASSAVA SCIENCES INC puts ($3.7M), BIOMEA FUSION INC puts ($2.8M), CORMEDIX INC calls ($920K), EDGEWISE THERAPEUTICS INC puts ($808K), ISHARES TR puts ($404K), INVESCO QQQ TR puts ($356K), SPDR SERIES TRUST puts ($311K), NEUMORA THERAPEUTICS INC. puts ($300K), LEXICON PHARMACEUTICALS INC calls ($282K), RELMADA THERAPEUTICS INC puts ($95K), SPDR SERIES TRUST calls ($22K), CANDEL THERAPEUTICS INC puts ($480).
Portfolio Sells Q3 2024 → Q4 2024 Portfolio Sells quarter Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024
Stock Change vs Q3 2024 % Of Portfolio Change To Portfolio ▲ CRMD Cormedix Inc. Sold out 0.00% −7.91 CYBIN INC Sold out 0.00% −6.34 CLRB Cellectar Biosciences Inc. Sold out 0.00% −5.21 ABEO Abeona Therapeutics Inc. Reduce -1.4% 5.42% −2.27 CMPS Compass Pathways PLC Reduce -9.4% 1.44% −1.83 OTLK Outlook Therapeutics Inc. Sold out 0.00% −1.59 VRNA Verona Pharma Ltd. Reduce -45.5% 3.75% −1.50 VERU Veru Inc. Sold out 0.00% −1.37 ABVX Abivax SA-ADR Sold out 0.00% −1.07 NSPR Inspiremd Inc. Reduce -0.7% 3.54% −0.93 OWLT Owlet Inc. Reduce -81.7% 0.12% −0.69 KPRX Kiora Pharmaceuticals Inc. Sold out 0.00% −0.62 FBIO Fortress Biotech Inc. Sold out 0.00% −0.48 DERM Journey Medical Corp. Sold out 0.00% −0.40 TLPH Talphera Inc. Reduce -19.1% 0.17% −0.26 NAMS Newamsterdam Pharma Co. NV Sold out 0.00% −0.11 CLEARSIDE BIOMEDICAL INC Sold out 0.00% −0.11 VOR Vor Biopharma Inc. Sold out 0.00% −0.04 MYO Myomo Inc. Reduce -0.7% 10.40% +2.36
Portfolio Buys Q3 2024 → Q4 2024 Portfolio Buys quarter Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024
Stock Change vs Q3 2024 % Of Portfolio Change To Portfolio ▼ CMRX Chimerix Inc. New 5.72% +5.72 URGN Urogen Pharma Ltd. New 4.99% +4.99 SVRA Savara Inc. New 4.39% +4.39 FENC Fennec Pharmaceuticals Inc. New 4.29% +4.29 HELP Cybin Inc. New 3.85% +3.85 VSTM Verastem Inc. New 2.51% +2.51 REPL Replimune Group Inc. New 1.70% +1.70 ACOG Alpha Cognition Inc. New 0.80% +0.80 TRVI Trevi Therapeutics Inc. Add +41.7% 2.36% +0.70 FLNA Filana Therapeutics Inc. New 0.53% +0.53 KPRX Kiora Pharmaceuticals Inc. New 0.45% +0.45 PROF Profound Medical Corp. Add +42.4% 2.80% +0.23 PYPD Polypid Ltd. Add +49.9% 1.67% +0.12 OCUL Ocular Therapeutix Inc. Add +27.5% 5.19% +0.08 BFRI Biofrontera Inc. Add +63.9% 0.48% +0.04 RLMD Relmada Therapeutics Inc. New 0.03% +0.03 OPTINOSE INC Add +58.7% 3.16% −0.53
Options Activity Q3 2024 → Q4 2024 Security Type Change vs Q3 2024 Underlying Shares Value ▼ CASSAVA SCIENCES INC put Add +13.6% 417,400 $3.7M BIOMEA FUSION INC put New 910,700 $2.8M CORMEDIX INC call Reduce -73.7% 183,900 $920K EDGEWISE THERAPEUTICS INC put New 237,500 $808K ISHARES TR put New 200,000 $404K INVESCO QQQ TR put New 100,000 $356K SPDR SERIES TRUST put New 800,000 $311K NEUMORA THERAPEUTICS INC. put New 136,600 $300K LEXICON PHARMACEUTICALS INC call New 1,278,900 $282K QQQ Invesco QQQ Trust Series 1 put Sold out 150,000 $221Kbefore exit XBI SS SPDR S&P Biotech ETF put Sold out 200,000 $164Kbefore exit RELMADA THERAPEUTICS INC put New 100,000 $95K SPDR SERIES TRUST call New 1,400,000 $22K CANDEL THERAPEUTICS INC put New 262,500 $480
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings Quarter Positions 13F Reported Value Top Holdings Q2 2026 29 $266.2M DCTH, FENC, XERS, SVRA, VSTM Q1 2026 32 $244.1M DCTH, XERS, FENC, SVRA, PCVX Q4 2025 29 $274.5M DCTH, SVRA, FENC, XERS, VRDN Q3 2025 29 $283.0M DCTH, CYTK, FENC, VSTM, RZLT Q2 2025 29 $206.6M DCTH, FENC, CYTK, OCUL, IDYA Q1 2025 31 $205.2M DCTH, VSTM, XERS, MYO, IDYA Q4 2024 Amended 28 $185.7M DCTH, MYO, MDWD, CMRX, XERS Q3 2024 29 $150.7M DCTH, MYO, CRMD, ABEO, MDWD Q2 2024 35 $126.5M DCTH, MYO, MDWD, OPTINOSE INC, ABEO Q1 2024 31 $106.9M MYO, LYRA, MDWD, OPTINOSE INC, XERS